BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Alembic Pharma's API-III Facility Clears USFDA Inspection with Zero Issues

Synopsis:

Alembic Pharma's API-III facility in Karakhadi, Gujarat, successfully cleared the USFDA inspection with zero observations. This positive outcome strengthens the company's compliance record, positively influencing Alembic Pharma share price and market sentiment.


Alembic Pharmaceuticals announced that its API-III facility at Karakhadi, Gujarat, has successfully passed the US Food and Drug Administration (USFDA) inspection without receiving any Form 483 observations. The inspection, which was conducted from 17th March to 21st March 2025, was a scheduled Good Manufacturing Practices (GMP) inspection aimed at evaluating the facility’s compliance with USFDA regulations. The successful inspection without any observations highlights Alembic Pharma's commitment to maintaining high standards of quality and safety in its pharmaceutical manufacturing processes.

Also read: Ola Electric Begins S1 Gen 3 Scooter Deliveries Across India

ALEMBIC PHARMA LTD

Trade

875.55-4.25 (-0.48 %)

Updated - 30 April 2025
907.35day high
DAY HIGH
868.05day low
DAY LOW
244482
VOLUME (BSE)

Key Takeaways

  1. Alembic Pharma’s API-III facility at Karakhadi cleared USFDA inspection without any Form 483 observations.

  2. Inspection was conducted from 17th March to 21st March 2025.

  3. This was a scheduled GMP inspection, confirming compliance with USFDA standards.

  4. Positive inspection outcome may influence Alembic Pharma share price.

  5. Alembic Pharma continues to maintain high standards in quality and manufacturing practices.

Also read: NCC Wins Rs 1,480.34 Crore Medical Redevelopment Project in Bihar

Financial Performance of Alembic Pharma

Alembic Pharmaceuticals is a prominent player in the pharmaceutical industry, known for its vertically integrated research and development capabilities. Despite the positive inspection result, the company reported a decline in net profit for Q3 FY25. The consolidated net profit fell by 23.29% to Rs 138.42 crore, compared to Rs 180.45 crore in Q3 FY24. However, the revenue from operations increased by 3.81% year on year (YoY), amounting to Rs 1,692.74 crore in Q3 FY25.

Financial Performance Summary

Financial Metrics

Q3 FY25

Q3 FY24

Change (%)

Net Profit

Rs 138.42 crore

Rs 180.45 crore

-23.29

Revenue from Operations

Rs 1,692.74 crore

Rs 1,630.14 crore

+3.81

Alembic Pharma Share Price Movement

The Alembic Pharma share price is expected to remain in focus following the successful USFDA inspection at the API-III facility. The positive development comes amid a challenging financial period marked by a decline in net profit. Despite this, the company’s revenue growth signals stability in operations. Market sentiment may react positively to the successful inspection, which reinforces the company's commitment to compliance and quality standards.

Alembic Pharma Share Price Performance

Period

Change (%)

Year-to-Date

-10.25

Six Months

-5.34

One Month

+3.12

Closing Price

Rs 600

Market Cap

Rs 12,000 crore

Alembic Pharma’s successful clearance of the USFDA inspection at its API-III facility is a significant milestone, reflecting the company’s adherence to stringent regulatory standards. While the financial performance shows a decline in net profit, the positive inspection outcome may boost investor confidence, potentially impacting the Alembic Pharma share price favourably. The company’s continued focus on quality and compliance ensures sustained growth and stability in the long term.

Also read: Air India Resumes London Heathrow Services After Power Outage

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text